| P50 | author | Supa Hannongbua | Q42871449 |
| P2093 | author name string | Pensri Srivab | |
| P2860 | cites work | Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase | Q27628304 |
| | The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance | Q27631898 |
| | Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors | Q27635069 |
| | Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant | Q27638329 |
| | High resolution structures of HIV-1 RT from four RT-inhibitor complexes | Q27729427 |
| | Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance | Q27766013 |
| | Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme | Q28291671 |
| | L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase | Q28378789 |
| | The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors | Q29039690 |
| | Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. | Q30342229 |
| | Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection | Q33631716 |
| | Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase | Q34047516 |
| | Antiviral drugs in current clinical use. | Q34547577 |
| | Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. | Q34575882 |
| | Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives | Q34595452 |
| | Modeling biotransformation reactions by combined quantum mechanical/molecular mechanical approaches: from structure to activity | Q35137594 |
| | New challenges in quantum chemistry: Quests for accurate calculations for large molecular systems | Q35153408 |
| | Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs | Q35796056 |
| | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). | Q36072382 |
| | Modelling enzyme reaction mechanisms, specificity and catalysis. | Q36299121 |
| | HIV reverse transcriptase structure-function relationships | Q36657162 |
| | The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations | Q39268433 |
| | TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 |
| | Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase | Q41346135 |
| | Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. | Q43678172 |
| | Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations | Q43979142 |
| | Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase | Q44570491 |
| | Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues | Q44844445 |
| | Quantum study of mutational effect in binding of efavirenz to HIV-1 RT. | Q46403165 |
| | Molecular mechanics PBSA ligand binding energy and interaction of Efavirenz derivatives with HIV-1 reverse transcriptase | Q46558469 |
| | Performance Evaluation of the Three-Layer ONIOM Method: Case Study for a Zwitterionic Peptide. | Q51629310 |
| | Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM. | Q51630551 |
| | Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V | Q57480046 |
| | Conformational study of the HIV-1 reverse transcriptase inhibitor 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) | Q77296519 |
| | Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives | Q80141775 |
| | Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method | Q81394699 |
| P433 | issue | 5 | |
| P921 | main subject | efavirenz | Q422645 |
| P304 | page(s) | 803-811 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method | |
| P478 | volume | 3 | |